Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Radio Pharma	33.88B	30.01B	25.52B	21.23B	-
Radio Pharma Growth	12.88%	17.59%	20.24%	-	-
Allergy Immunotherapy	7.14B	6.98B	6.03B	4.89B	-
Allergy Immunotherapy Growth	2.36%	15.76%	23.15%	-	-
Contract Development and Manufacturing Organization - Sterile Injectables	13.53B	12.04B	12.71B	14.35B	-
Contract Development and Manufacturing Organization - Sterile Injectables Growth	12.31%	-5.24%	-11.43%	-	-
Contract Research, Development and Manufacturing Organization	11.73B	11.40B	12.93B	11.48B	-
Contract Research, Development and Manufacturing Organization Growth	2.88%	-11.82%	12.58%	-	-
Generics	6.85B	7.75B	7.65B	11.62B	-
Generics Growth	-11.53%	1.23%	-34.13%	-	-
Inter-Segment Revenue	-1.16B	-1.53B	-2.28B	-2.49B	-240.39M
Unallocable Corporate	372.00M	383.00M	218.00M	202.49M	-
Unallocable Corporate Growth	-2.87%	75.69%	7.66%	-	-
Proprietary Novel Drugs	-	-	38.00M	18.41M	36.65M
Proprietary Novel Drugs Growth	-	-	106.41%	-49.77%	-63.47%
Pharmaceuticals (Excluding Drug Discovery and Development Solutions)	-	-	-	-	57.90B
Pharmaceuticals (Excluding Drug Discovery and Development Solutions) Growth	-	-	-	-	1.32%
Contract Research and Development Services (Excl. Proprietary Novel Drugs)	-	-	-	-	3.29B
Contract Research and Development Services (Excl. Proprietary Novel Drugs) Growth	-	-	-	-	21.18%
Total	72.35B	67.03B	62.82B	61.30B	60.99B
Total Growth	7.93%	6.71%	2.47%	0.52%	2.05%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
India	2.13B	1.92B	1.91B	3.39B	19.75B
India Growth	10.78%	0.73%	-43.85%	-82.81%	-2.73%
Americas and Europe	65.94B	60.12B	55.94B	53.19B	61.16B
Americas and Europe Growth	9.67%	7.48%	5.15%	-13.02%	-4.01%
Rest of The World (ROW)	4.28B	4.99B	4.98B	4.71B	5.90B
Rest of The World (ROW) Growth	-14.17%	0.24%	5.57%	-20.08%	11.22%
China	-	-	-	-	2.25B
China Growth	-	-	-	-	1.04%
Discontinued Operations	-	-	-	-	-28.07B
Total	72.35B	67.03B	62.82B	61.30B	60.99B
Total Growth	7.93%	6.71%	2.47%	0.52%	2.05%

Source: S&P Global Market Intelligence.